Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

Search the Community

Showing results for tags 'rootsanalysis'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • CRIME
    • General Chat on Crime
    • Forum about the Famous Criminals in the history.
    • Victims of Crimes Against the Person
    • Forum on Sexual Offences
    • Victims of Crimes against Property
    • Forum on Crimes against the Public
    • Forum on Self Defence and Defence of Property
  • CRIMINAL JUSTICE
    • General Chat on Criminal Justice
    • Forum on the punishment of the perpetrators of crimes
    • Forum on the conditions of life of Prisoners in Prison
    • Forum on Juvenile Delinquency
  • CRIMINAL LAW
    • General Chat on Criminal Law
    • Forum on the Death Penalty and Torture
    • Forum on proposals for reform of criminal law
    • Forum on the legalization of soft drugs.
  • HOME SECURITY
    • General Chat on Home Security Systems
    • Forum on Gun Control
  • LAW ENFORCEMENT
    • General Chat on Law Enforcement
    • Forum on Federal Bureau of Investigation (FBI)
    • Forum on Drug Enforcement Administration (DEA)
    • Forum on Law enforcement in the United Kingdom
    • Forum on Law enforcement in Canada, Australia, New Zealand and Ireland
  • Blog against the Death Penalty and Torture's Death Penalty and Torture in the world

Blogs

  • Blog in favor of legalization of soft drugs
  • Increase Gun Control in the United States and particularly in California.
  • The drug repurposing service providers market is estimated to be worth USD 1.2 billion in 2030
  • Growing at an annualized rate of over 9%, the antibody discovery services market
  • The global digital biomarkers market is projected to be worth over USD 22 billion by 2030

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


About Me

  1. Key Inclusions § An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters, such as status of development (developed and under development), affiliated approach, type of compatible pharmacological molecule(s) crossing the BBB (small molecule and biologic), target receptor(s), target disease indication(s), patent availability, and licensing activity. In addition, it presents a detailed assessment of BBB technology developers and analyses based on parameters, such as year of establishment, compan
  2. Roots Analysis has done a detailed study on Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this https://www.rootsanalysis.com/reports/310/request-sample.html Key Market Insights § More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treat
  3. Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.” The report features an extensive study of the current market landscape, offering an in
  4. Key Inclusions § A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment. § A comprehensive list of novel technology platforms that are either currently available or being developed by various firms for the generation o
  5. With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years. To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html The USD 6.9 bill
  6. Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html Key Market Insights § With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody therapeutics pipeline has evolved significantly over the pas
  7. Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of ‘two-target’ artificially engineered drugs have generated significant enthusiasm within the medical science community Roots Analysis is pleased to announce the publication of its recent study, titled, “Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study
  8. Key Inclusions § A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment,
  9. Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs
  10. Roots Analysis has done a detailed study on Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link Key Market Insights § Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products. § The market landscape is highly fragmented featuring the presence of both established
  11. Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.” The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of bio
  12. Key Inclusions § A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory), type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both)
  13. Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products. To order this 480+ page report, which features 350+ figures and 260+ tables, please visit this link The USD 4.2 billion (by 2030) financial opportunity within the biologics fill / finish services market has b
  14. Roots Analysis has done a detailed study on Biologics Fill / Finish Services Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 480+ page report, which features 237 figures and 267 tables, please visit this link Key Market Insights § Over 115 companies located in various regions across the globe claim to provide contract fill / finish services for various types of biopharmaceutical drug / therapy products § The market landscape features a mix of both established players an
  15. A steadily growing demand for biologic fill / finish services has generated a range of new opportunities for contract service providers; stakeholders have invested heavily to ensure product integrity and safety Roots Analysis is pleased to announce the publication of its recent study, titled, “Biologics Fill / Finish Services Market, 2019-2030.” The report features an extensive study on the contract service providers offering drug product manufacturing services within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of
  16. Over time, various pharma players have taken advantage of these immersive technologies for education, training as well as marketing, purposes. These technologies have been demonstrated to be capable of driving better customer engagement, and generating useful insights based on their expectations and purchase behaviors. Given the increasing demand for immersive technologies in the healthcare and pharma marketing, several stakeholders are expected to forge alliances with AR / VR service providers in the foreseen future. Owing to the rising interest of big pharma players in this domain, we expect
  17. Roots Analysis has done a detailed study on “AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 180+ page report, which features 45+ figures and 70+ tables, please visit this link Key Market Insights § Presently, more than 120 companies claim to offer AR / VR and affiliated digital marketing services to the global healthcare industry § In the last five years, several companies have entered this domain, offering a
  18. Roots Analysis has announced the addition of “AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030” report to its list of offerings. Over time, various pharma players have taken advantage of these immersive technologies for education, training as well as marketing, purposes. These technologies have been demonstrated to be capable of driving better customer engagement, and generating useful insights based on their expectations and purchase behaviors. Given the increasing demand for immersive technologies in the healthcare and pharma marketing, several stake
  19. Key Inclusions § A detailed assessment of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of linker, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target indication(s), line of treatment, route of administration and dosing frequency. § Elaborate p
  20. With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects. To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link The USD 15 billion (by 2030) financial opportunity within this market has been analyz
  21. Key Market Insights § Eminent representatives from different biopharmaceutical companies confirm the sustained interest in ADC therapeutics, highlighting the technological innovation that is driving contemporary R&D initiatives § Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers § The pipeline features product candidates that target a wide range of biological antigens and are equipped with different cytotoxic warheads; a number of companies are focused on developing
  22. Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatment; over the years, this upcoming class of targeted therapeutic agents has generated significant enthusiasm within the medical science community Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Drug Conjugates Market (5th Edition), 2019-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth ana
  23. Key Inclusions § An overview of the overall landscape of antibody discovery service providers along with the information on a number of parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal
  24. According to experts in this field, the industry is investigating antibodies against novel targets which are expected to drive the market in the coming years. In fact, many service provider and platform provider companies are offering support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus. To order this 500+ page report, which features 120+ figures and 140+ tables, please visit this link The USD 6.5 billion (by 2030) financial opportunity within the antibody discovery services market
×
  • Create New...